The mission of Alderaan Biotechnology is to develop novel therapies to treat cancer by targeting cells from the immune system. Alderaan Biotechnology programs are related to the elimination of Regulatory T cells and to the hyper activation of Natural Killer cells in the tumor microenvironment. The company programs are based on the research of its founding scientists on the use of monoclonal antibodies targeting immune cells to treat cancers. The objective of Alderaan Biotechnology is to develop new antibodies targeting NK cells through CD160-TM and Treg cells through CD25, with oncology as the sole indication focus.
Find locations served, office locations
- Business Type:
- Industry Type:
- Clinical Services
- Market Focus:
- Nationally (across the country)